9 results
Primary objectives• To identify the percentage of patients in which a drug resistant clone can be detected with ctDNA before the emergence of radiological progression.• To determine the success rate of crizotinib and osimertinib combination…
To investigate the effect of a CYP3A4 inhibitor (itraconazole) on the PK of AZD9291.
To investigate the effect of a CYP3A4 inducer (rifampicin) on the PK of AZD9291.
To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)Protocol v1.0, 4Jun2015, p30
• to assess the efficacy of the sequential combination strategy of front-line afatinib-chemo, followed by a treatment with osimertinib-chemo in those patients that develop a T790M mutation as a mechanism of resistance.
The primary goal of this study is to describe possible causes of gait asymmetry in patients with an endoprosthetic reconstruction of the knee joint due to a bone tumour. Therefore, the assumed gait asymmetry is first verified (part A). Subsequently…
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Primary objective:- To assess the efficacy of durvalumab with SoC SBRT compared to placebo with SoC SBRT in terms of PFS in patients with subset of T1 to T3N0 NSCLCOsimertinib cohort:- To assess the efficacy of osimertinib following SoC SBRT by 4…
Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial.
To determine the efficacy (as assessed by best response) of osimertinib in patients with locally advanced or metastatic NSCLC and only an EGFR exon 20 mutation, deletion and/or insertion, which are T790M-ve.